丁苯酞联合依达拉奉治疗进展性脑梗死的疗效及对神经功能缺损和血液流变学的影响

发布时间：2018-06-13 15:39

本文选题：丁苯酞 + 依达拉奉　；参考：《中国医药指南》2016年30期

【摘要】：目的探究进展性脑梗死患者采用丁苯酞与依达拉奉的应用效果。方法选取本院2013年10月至2015年4月收治的86例进展性脑梗死患者,抽签分为2组。两组均接受常规治疗,在此基础上对照组43例采用依达拉奉治疗,观察组43例采用丁苯酞与依达拉奉治疗。并对两组神经功能缺损评分、血液流变学变化、不良反应进行对比。结果对照组的有效率低于观察组(67.44%vs 88.37%),(P0.05);治疗后,两组神经功能缺损评分均有所降低,但观察组的下降幅度明显优于对照组(P0.05);治疗后,两组的纤维蛋白质、血浆黏度与血小板聚集均有降低,且观察组的降低幅度明显优于对照组(P0.05);两组患者不良反应的对比(P0.05)。结论丁苯酞与依达拉奉使进展性脑梗死患者的神经功能缺损症状有效改善,使纤维蛋白含量、血小板聚集以及血液黏度有效降低。
[Abstract]:Objective to investigate the effect of butyphthalide and Edaravone in patients with progressive cerebral infarction. Methods 86 patients with progressive cerebral infarction from October 2013 to April 2015 were divided into 2 groups. On this basis, 43 cases in control group were treated with Edaravone, 43 cases in observation group were treated with butyphthalide and Edaravone. The neurological impairment scores, hemorheological changes and adverse reactions were compared between the two groups. Results the effective rate of the control group was lower than that of the observation group (67.44 vs 88.37). After treatment, the neurological deficit score of the two groups was decreased, but the decrease of the observation group was obviously better than that of the control group (P 0.05). The decrease of plasma viscosity and platelet aggregation was significantly higher in the observation group than in the control group (P 0.05), and the adverse reactions in the two groups were compared with that in the control group (P 0.05). Conclusion butyphthalide and Edaravone can effectively improve the neurological deficit symptoms and decrease fibrin content platelet aggregation and blood viscosity in patients with progressive cerebral infarction.
【作者单位】：锦州市第二医院神经内科;
【分类号】：R743.33

【相似文献】